Sentence examples for bms from inspiring English sources

Suppose N to be the average number of shocks per year for which the magnitude lies in a range about Ms. Thenlog10 N = a − bMs fits the data well both globally and for particular regions; for example, for shallow earthquakes worldwide, a = 6.7 and b = 0.9 when Ms > 6.0.

He claims BMS used its insider knowledge about his proposal for a split (BMS has its own man on ImClone's board) to make a pre-emptive bid, so it could buy the firm at a cheaper price.

Its main product is Erbitux, a cancer drug jointly marketed with BMS that brings in $1.3 billion a year in sales.

BMS rejects his allegations and insists ImClone would be most valuable if fully integrated into BMS a notion that sends shivers down the spines of pharma-haters in the biotech camp.To see how difficult it can be even for Mr Icahn to get his way, look to the saga at Biogen Idec, another American biotech firm in which the gadfly billionaire owns a stake.

Rather than selling the entire company to BMS, Mr Icahn wants it split into two bits: one containing Erbitux and the other inheriting ImClone's future drug-pipeline.

That is because the recent good news has cleared away thorny legal obstacles that made BMS hard to value properly for any potential bidder.

In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world's biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb BMSS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control.

This week Eli Lilly, a medium-sized American drugs firm, outbid Bristol-Myers Squibb BMSS), another middling American rival, for ImClone, a coveted biotechnology firm.

In a new report analysts at Credit Suisse, an investment bank, argue that Britain's GlaxoSmithKline and Switzerland's Novartis are the most "natural acquirers" today, with Britain's Astra Zeneca and America's Wyeth and Bristol-Myers Squibb BMSS) as the "natural targets" in the next wave of consolidation.Julien Dormois of Bryan Garnier, an investment bank, goes further.

THE past year has not been a good one for Bristol-Myers Squibb BMSS), a middling American pharmaceutical firm widely rumoured to be a takeover target.

And the removal of Peter Dolan from the top job at Bristol-Myers Squibb BMSS) this week came as a result of his mishandling of a challenge posed to Plavix, the company's lucrative blood-thinning drug, by a generic rival.